Bain Capital Life Sciences Investors, LLC
Annual return '25
-17.9%
SPY '25
+17.7%
Alpha
-35.6ptsvs SPY
Invested
$1.1B
Holdings
19
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 78%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$HTFL
HEARTFLOW INC
Held since at least Q1 2024
23.0%
02
$NAMS
NEWAMSTERDAM PHARMA COMPANY
Held since at least Q1 2024
21.1%
03
$OLMA
OLEMA PHARMACEUTICALS INC
Held since at least Q1 2024
10.1%
04
$SVRA
SAVARA INC
Held since at least Q1 2024
8.7%
05
$PHVS
PHARVARIS N V
Held since at least Q1 2024
6.8%
06
$SLDB
SOLID BIOSCIENCES INC
Held since at least Q1 2024
6.4%
07
$XFOR
X4 PHARMACEUTICALS INC
Held since at least Q1 2024
3.0%
08
$DNTH
DIANTHUS THERAPEUTICS INC
Held since at least Q1 2024
2.7%
09
$ANNX
ANNEXON INC
Held since at least Q1 2024
2.6%
10
$KYTX
KYVERNA THERAPEUTICS INC
Held since at least Q1 2024
2.4%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 09:44 UTC.